» Articles » PMID: 35139567

Ovarian Tissue Culture to Preserve Fertility in Transgender Male Patients After Hormonal Treatment

Overview
Date 2022 Feb 9
PMID 35139567
Authors
Affiliations
Soon will be listed here.
Abstract

Objective:  To evaluate the reproductive and histological characteristics of fresh cultured ovarian tissue from transgender male patients.

Methods:  An in vitro pilot study in which samples were collected during sex reassignment surgery for transgender male patients. The ovarian cortex was cut into fragments of 2 mm, 3 mm, and 4 mm, and placed in a 96-well plate suitable for cultivation at days 0, 2, 4, 6, and 8, when the histology was analyzed.

Results:  Stromal hyperplasia was observed in all samples, and it was not associated with the obtainment of primordial or primary follicles. Peripheral reduction in cell count was also a recurrent finding. Primordial and primary follicles were identified with a heterogeneous pattern in fragments from the same patient and from different patients, and follicles in more advanced stages of development (secondary and antral) were not found. There was an association between the diameter of the ovarian fragments and the identification of primary follicles ( = 0.036). The number of days in culture was associated with histological signs of tissue damaging in the fragments ( = 0.002). The total number of follicles identified in the samples with 2 mm in diameter was significantly lower than in those that measured 4 mm in diameter ( = 0.031).

Conclusion:  A diameter of 4 mm is suitable for ovarian tissue culture with the benefit of ease of handling. Even after prolonged exposure to testosterone, the ovarian fragments presented primordial and primary follicles, maintaining viability throughout the days they were exposed to the culture. Freezing the ovarian cortex of transgender patients who will undergo surgery for gender reassignment would be an interesting option, in the future, for the preservation of fertility.

Citing Articles

Clinical management of transgender and non-binary patients in the fertility preservation service: Current evidence.

Tsonis O, Kopeika J Int J Transgend Health. 2024; 25(4):663-680.

PMID: 39465086 PMC: 11500512. DOI: 10.1080/26895269.2023.2284775.


"Lights and Shades" of Fertility Preservation in Transgender Men Patients: A Clinical and Pathological Review.

Damato A, Cascardi E, Etrusco A, Lagana A, Schonauer L, Cazzato G Life (Basel). 2023; 13(6).

PMID: 37374095 PMC: 10305315. DOI: 10.3390/life13061312.

References
1.
Emadi A, Jones R, Brodsky R . Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009; 6(11):638-47. DOI: 10.1038/nrclinonc.2009.146. View

2.
Van Den Broecke R , Van Der Elst J , Liu J, Hovatta O, Dhont M . The female-to-male transsexual patient: a source of human ovarian cortical tissue for experimental use. Hum Reprod. 2001; 16(1):145-147. DOI: 10.1093/humrep/16.1.145. View

3.
Hussein R, Khan Z, Zhao Y . Fertility Preservation in Women: Indications and Options for Therapy. Mayo Clin Proc. 2020; 95(4):770-783. DOI: 10.1016/j.mayocp.2019.10.009. View

4.
Pache T, Chadha S, Gooren L, Hop W, Jaarsma K, Dommerholt H . Ovarian morphology in long-term androgen-treated female to male transsexuals. A human model for the study of polycystic ovarian syndrome?. Histopathology. 1991; 19(5):445-52. DOI: 10.1111/j.1365-2559.1991.tb00235.x. View

5.
Schmidt K, Byskov A, Nyboe Andersen A, Muller J, Andersen C . Density and distribution of primordial follicles in single pieces of cortex from 21 patients and in individual pieces of cortex from three entire human ovaries. Hum Reprod. 2003; 18(6):1158-64. DOI: 10.1093/humrep/deg246. View